

TABLE OF CONTENTS

Book 2

Preface	i
Editorial Board	ii
Book 2 Panel	iii
Disclosure of Potential Conflicts of Interest	vii
Continuing Education and Program Evaluation Instructions	x
Roles of ACCP and BPS	xiii

Nephrology I

CONTROVERSIES IN ASSESSING KIDNEY FUNCTION

Learning Objectives	1
Introduction	1
Evaluation of Glomerular Filtration Rate	1
Serum Cystatin C	1
Creatinine Clearance	2
Estimated GFR Using MDRD Equations	3
Standardization of Creatinine Assay in Clinical Laboratories	4
Elderly	5
Patients who are Critically Ill and Hospitalized	5
Drug Dosing in Kidney Disease	5
Update in Pediatrics	6
Assessment of Proteinuria	6
Conclusion	7
Annotated Bibliography	7
Self-Assessment Questions	11

ANEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE

Learning Objectives	15
---------------------------	----

Introduction	15
Definition of Anemia	15
Prevalence	15
Outcomes of Anemia	15
Therapeutic Goals	16
Role of Blood Transfusions	17
Quality Patient Care	17
Pharmacotherapy	17
Erythropoiesis-Stimulating Agents	17
Adjunctive Therapy with ESAs	19
Iron Therapy	19
Functional Iron Deficiency Versus Absolute Iron Deficiency	20
The Ferritin Controversy	20
Safety of Parenteral Iron in Patients Receiving HD	20
Safety of Long-Term Intravenous Iron	21
New Iron Tests	21
Ascorbic Acid	22
Levocarnitine	22
Treatment Plan	22
KDOQI Anemia Guideline Update	22
Monitoring	22
Treatment of ESA Hyporesponsiveness	24
Inflammation	24
Secondary Hyperparathyroidism	25
Hospitalization	25
Drugs	25
Pure Red Cell Aplasia	25
Patient Education	26
Quality Improvement	26
Annotated Bibliography	27
Self-Assessment Questions	31
CONTROVERSIES IN TREATING CARDIOVASCULAR DISEASE IN PATIENTS WITH CHRONIC KIDNEY DISEASE	
Learning Objectives	35
Introduction	35

Definitions	35
Controversy in Pathophysiologic Link Between CKD and CVD	35
Etiology	35
CKD and Hypertension	35
CKD and Congestive Heart Failure	36
Anemia in CHF and CKD	37
CKD and Coronary Artery Disease	37
Management	38
Hypertension	38
Congestive Heart Failure	38
Acute Congestive Heart Failure	38
Diuresis	38
Nesiritide	39
Chronic Congestive Heart Failure	39
Digoxin	39
Renin-Angiotensin Blockade	39
Anemia	40
Coronary Artery Disease	40
Troponin and CKD	40
Sympathetic Drive and Renin-Angiotensin Activity	40
Hyperlipidemia	41
HMG CoA Reductase Inhibitor Safety in CKD	43
Arterial Calcification	43
Kidney Protection During Angioplasty	44
Patient Education	45
Quality Pharmaceutical Care	45
Summary Recommendations	45
Annotated Bibliography	45
Self-Assessment Questions	49

Nephrology II

BONE METABOLISM AND DISEASE IN CHRONIC KIDNEY DISEASE

Learning Objectives	55
Introduction	55
Pathophysiology	55
Derangements of Phosphorus, Calcium, Vitamin D, and PTH Balance	55
Diagnosis of Bone Disease	56
Vitamin D	57
Prevalence of CKD-MBD	58
Consequences of CKD-MBD	58
Quality of Life	58
Mortality	58
Goals of Therapy	58
Restriction of Dietary Phosphorus	59
Pharmacotherapy	59
Phosphate-Binding Agents	59
Aluminum-Containing Phosphate Binders	59
Calcium-Containing Phosphate Binders	60
Newer Phosphate Binders	61
Vitamin D Therapy	62
Calcimimetics	63

Parathyroidectomy	63
Therapeutic Challenges	64
Adherence	64
Conclusion	65
Annotated Bibliography	65
Self-Assessment Questions	69

CONTRAST-INDUCED NEPHROPATHY

Learning Objectives	73
Introduction	73
Pathophysiology	73
Definition	73
Pathogenesis/Mechanism	73
Risk Factors	74
Clinical Characteristics and Epidemiology	74
Therapeutic Goals/Outcomes	74
Quality Patient Care	74
Prevention of CIN	74
Nonpharmacological Therapy	74
Hemodialysis	74
Hemofiltration	75
Pharmacological Therapy	75
Fluids	75
Antioxidants	76
N-Acetylcysteine	76
Ascorbic Acid	77
Inhibitors of Renal Vasoconstriction	77
Theophylline and Aminophylline	77
Fenoldopam	80
Calcium Channel Blockers	80
Other Therapies	80
Carbon Dioxide	80
Hydroxymethyl Glutaryl-Coenzyme A Reductase Inhibitors	80
Prostaglandin E1 and L-Arginine	81
Implementing Plans for Prevention	81
Algorithm and Guidelines	81
Special Populations	81
Role of the Pharmacist	81
Monitoring	81
System Support for Medication Use and Quality Improvement	81
Patient Education	81
Conclusion	82
Addendum	82
Annotated Bibliography	83
Self-Assessment Questions	87

DRUG ISSUES IN RENAL REPLACEMENT THERAPIES

Learning Objectives	91
Introduction	91
Indications for Renal Replacement Therapy	91
Renal Replacement Therapy Modalities	91
Intermittent Hemodialysis	92
Access	92

Operational Characteristics	92
Dialyzers	92
Anticoagulation	92
Complications of Intermittent Hemodialysis	
Procedures	93
Access-Related Complications	93
Continuous Renal Replacement Therapies	95
Access	95
Operational Characteristics	95
Anticoagulation	95
Complications of Continuous Renal Replacement Therapies	95
Peritoneal Dialysis	96
Access Creation	96
Operational Characteristics	96
Complications of Peritoneal Dialysis	96
Exit-Site Infections	97
Peritonitis	97
Drug Dosing in RRTs	97
Estimation of Drug Clearance	97
Patient-Specific Factors	98
Drug-Specific Factors	98
Administration Route	98
Renal Replacement Therapy-Specific Factors	99
Drug Dosing Strategies	99
Therapeutic Drug Monitoring	99
The Role of the Pharmacist	100
Annotated Bibliography	100
Self-Assessment Questions	103

Dyslipidemia	113
Screening	113
Quality Patient Care	113
Obesity	115
Quality Patient Care	115
Smoking	115
Quality Patient Care	115
Anemia	116
Quality Patient Care	116
Post-Transplant Erythrocytosis	116
Proteinuria	116
Hyperhomocysteinemia	116
Modification of Immunosuppression to Reduce CV Risk	116
Additional Long-Term Issues in Recipients of a Kidney Transplant	117
Reproductive Issues	117
Issues in Women	117
Issues in Men	118
Hyperparathyroidism and Bone Disease	118
Hyperuricemia and Gout	119
Malignancy	119
Preventive Care	119
Lifestyle Modification	120
Adherence	120
Role of the Pharmacist	120
Conclusion	120
Annotated Bibliography	120
Self-Assessment Questions	123

Nephrology III

LONG-TERM COMPLICATIONS OF KIDNEY TRANSPLANTATION	
Learning Objectives	109
Introduction	109
Leading Causes of Allograft Loss	109
Death with Function	109
Cardiovascular Disease	109
Screening	110
Quality Patient Care	110
Chronic Allograft Nephropathy	110
Screening, Prevention, and Diagnosis	110
Quality Patient Care	110
Modification of the Immunosuppression Regimen	110
Management of Comorbid Conditions	111
Important Modifiable Risk Factors in Recipients of a Kidney Transplant	111
Diabetes Mellitus	111
Screening	111
Diagnosis	111
Quality Patient Care	111
Hypertension	112
Screening	112
Quality Patient Care	112

PHARMACOGENOMICS AND KIDNEY TRANSPLANTATION	
Learning Objectives	127
Introduction	127
Pharmacogenetic Effects on Pharmacokinetics/Pharmacodynamics	128
Drug Disposition Markers	128
CYP3A4/5 Enzymes	128
Membrane Transporters	128
Multidrug Resistance-Associated Protein 2	129
Thiopurine S-Methyltransferase	129
Uridine Diphosphate Glucuronosyltransferase 1A9	130
Application of Pharmacogenetics to Pharmacokinetics of Immunosuppressants in Recipients of Transplants	130
Tacrolimus	130
Cyclosporine	131
Sirolimus	131
Corticosteroids	131
Mycophenolic Acid	131
Effects of P-gp on Pharmacodynamics in Recipients of Transplants	132
Drug Resistant Rejection	132
Corticosteroid Resistance	132
Calcineurin Nephrotoxicity	132
Corticosteroid-Induced Osteonecrosis	132

Patient Survival	132
Drug Targets	133
Cytokines	133
Interleukin-10	133
Tumor Necrosis Factor- α	133
Interleukin-6	133
Transforming Growth Factor- β 1	134
Interferon- γ	134
Adhesion Molecules	134
Inosine Monophosphate Dehydrogenase	134
Future Applications of Pharmacogenomics in Kidney	
Transplantation	134
Annotated Bibliography	135
Self-Assessment Questions	139

MANAGEMENT OF EARLY COMPLICATIONS OF KIDNEY TRANSPLANTATION

Learning Objectives	143
Introduction	143
Organ Recovery-Related Complications	143
Preoperative Complications	143
Pharmacological Support to Maintain Organ	
Viability	144
Hemodynamic Support	144
Combined Hormonal Therapy	144
Reperfusion Injury	145
Perioperative Complications	145
Cardiovascular and Hemodynamic Complications	145
Surgical Complications	145
Hemorrhage	145
Renal Artery and Vein Thrombosis	146
Urological Complications	146
Lymphocele Complications	146
Immunosuppression-Induced Surgical	
Complications	146
Other Early Complications	147
Delayed Allograft Function	147
Immunological Complications	148
Immunological Testing and Risk Stratification	148
Acute Rejection	148
Antibody Mediated Rejection	149
Cellular Rejection	149
Metabolic Complications	149
Complications of Immunosuppressive Drug	
Therapy	150
Infection and Malignancy	150
Lymphocyte-Depleting Antibody Drugs	151
Calcineurin Inhibitors	151
Antiproliferative Drugs	152
Sirolimus	152
Patient Care	152
Conclusion	153
Annotated Bibliography	153
Self-Assessment Questions	157